World Journal of Surgery

, Volume 33, Issue 8, pp 1626–1632 | Cite as

Use of Leukoreduced Blood Does Not Reduce Infection, Organ Failure, or Mortality Following Trauma

  • Michael S. Englehart
  • S. David Cho
  • Melanie S. Morris
  • Arvin C. Gee
  • Gordon Riha
  • Samantha J. Underwood
  • Jerome A. Differding
  • Nick D. Luem
  • Tracy T. Wiesberg
  • Lynn K. Boshkov
  • Martin A. Schreiber



Leukoreduced (LR) blood has been demonstrated to reduce morbidity and mortality in high-risk surgical patients, but not in trauma patients. The objective of the present study was to determine the effect of LR blood on morbidity and mortality. We hypothesized that the use of LR blood does not improve outcome in trauma patients.


This study was a retrospective cohort analysis of trauma patients transfused at a level 1 Trauma Center from 2001 to 2004. Between 2002 and 2003, LR blood was transfused. Prior to that time and subsequent to it, non-leukoreduced (NLR) blood was transfused. This created two historical comparison groups. Data collected included patient demographics, units of blood transfused, intensive care unit (ICU) and hospital days, ventilator days, injury severity score (ISS), mortality, presence of acute respiratory distress syndrome (ARDS), and infectious complications. A multiple organ dysfunction syndrome (MODS) score was calculated.


The distribution of patients was as follows: 284 patients received only NLR blood, 153 received only LR blood, and 58 received at least one unit of each. The mean ISS was similar (NLR: 26, LR: 24; P > 0.1). No differences were seen between groups in units transfused (6.2 vs. 5.5), number of ICU days (8.2 vs. 9.0), number of hospital days (16.9 vs. 18.6), number of ventilator days (6.1 vs. 5.7), incidence of ARDS (8.3% vs. 8.5%), MODS score (5.5 vs. 5.9), mortality rate (15.1% vs. 15.7%), or infection rate (36% vs. 30%) (P > 0.1).


This study represents the largest series comparing trauma patients who received either LR or standard blood transfusions. The use of LR blood does not improve outcome in trauma patients.


  1. 1.
    Shapiro MJ, Gettinger A, Corwin HL et al (2003) Anemia and blood transfusion in trauma patients admitted to the intensive care unit. J Trauma 55:269–274PubMedCrossRefGoogle Scholar
  2. 2.
    American College of Surgeons Committee on Trauma (1997) Advanced trauma life support course for doctors. Chicago, American College of Surgeons, pp 87–107Google Scholar
  3. 3.
    Malone DL, Dunne J, Tracy JK et al (2003) Blood transfusion, independent of shock severity is associated with worse outcome in trauma. J Trauma 54:898–907PubMedCrossRefGoogle Scholar
  4. 4.
    Hill GE, Frawley WH, Griffith KE et al (2003) Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma 54:908–914PubMedCrossRefGoogle Scholar
  5. 5.
    Uhlmann EJ, Isgriggs E, Wallhermfechtel M et al (2001) Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 41:997–1000PubMedCrossRefGoogle Scholar
  6. 6.
    Yazer MH, Podlosky L, Clarke G et al (2004) The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 44:10–15PubMedCrossRefGoogle Scholar
  7. 7.
    Sillman CC, Boshkov LK, Mehdizadehkashi Z et al (2003) Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 101:454–462CrossRefGoogle Scholar
  8. 8.
    Sayers MH, Anderson KC, Goodnough LT et al (1992) Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 116:55–62PubMedGoogle Scholar
  9. 9.
    Pamphilon DH, Rider JR, Barbara JA et al (1999) Prevention of transfusion-transmitted cytomegalovirus infection. Transfusion Med 9:115–123CrossRefGoogle Scholar
  10. 10.
    Donegan E, Lee H, Operskalski EA et al (1994) Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 34:478–483PubMedCrossRefGoogle Scholar
  11. 11.
    Opelz G, Vanrenterghem Y, Kirste G et al (1973) Prospective evaluation of pretransplant blood transfusions on subsequent kidney transplants. Transplant Proc 5:253–259PubMedGoogle Scholar
  12. 12.
    Bordin JO, Blajchman MA (1995) Immunosuppressive effects of allogeneic blood transfusions: implications for the patient with a malignancy. Hematol Oncol Clin North Am 9:205–218PubMedGoogle Scholar
  13. 13.
    Roddie PH, Turner ML, Williamson LM (2000) Leucocyte depletion of blood components. Blood Rev 14:145–156PubMedCrossRefGoogle Scholar
  14. 14.
    Jensen LS, Andersen AJ, Christiansen PM et al (1992) Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 79:513–516PubMedCrossRefGoogle Scholar
  15. 15.
    Jensen LS, Hokland M, Nielsen HJ (1996) A randomized controlled study of the effect of bedside leucocyte depletion on the immunosuppressive effect of whole blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 83:973–977PubMedCrossRefGoogle Scholar
  16. 16.
    Aiboshi J, Moore EE, Ciesla DJ et al (2001) Blood transfusion and the two-insult model of post-injury multiple organ failure. Shock 15:302–306PubMedCrossRefGoogle Scholar
  17. 17.
    King KE, Shirey RS, Thoman SK et al (2004) Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 44:25–29PubMedCrossRefGoogle Scholar
  18. 18.
    Paglino JC, Pomper GJ, Fisch GS et al (2004) Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 44:16–24PubMedCrossRefGoogle Scholar
  19. 19.
    Bordin JO, Chiba AK, Carvalho KL et al (1999) The effect of unmodified or prestorage white cell-reduced allogeneic red cell transfusions on the immune responsiveness in orthopedic surgery patients. Transfusion 39:718–723PubMedCrossRefGoogle Scholar
  20. 20.
    Sparrow RL, Patton KA (2004) Supernatant from stored red blood cell primes inflammatory cells: influence of prestorage white cell reduction. Transfusion 44:722–730PubMedCrossRefGoogle Scholar
  21. 21.
    Fransen EJ, Rombout-Sestrienkova E, van Pampus ECM et al (2002) Prestorage leucocyte reduction of red cell components prevents release of bactericidal permeability increasing protein and defensins. Vox Sang 83:119–124PubMedCrossRefGoogle Scholar
  22. 22.
    Fung MK, Rao N, Rice J et al (2004) Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study. Transfusion 44:30–35PubMedCrossRefGoogle Scholar
  23. 23.
    Wallis JP, Chapman CE, Orr KE et al (2002) Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 42:1127–1134PubMedCrossRefGoogle Scholar
  24. 24.
    Fergusson D, Hebert PC, Barrington KJ et al (2002) Effectiveness of WBC reduction in neonates: what is the evidence of benefit? Transfusion 42:159–165PubMedCrossRefGoogle Scholar
  25. 25.
    Hebert PC, Fergusson D, Blajchman MA et al (2003) Clinical outcomes following institution of the Canadian Universal Leukoreduction Program for Red Blood Cell Transfusions. JAMA 289:1941–1949PubMedCrossRefGoogle Scholar
  26. 26.
    Athens AB, Nester TA, Urbanely GD et al (2006) Effects of leukoreduced blood transfusion on infection risk following injury: a randomized controlled trial. Shock 26:342–347CrossRefGoogle Scholar
  27. 27.
    Fergusson D, Hanna MP, Tinmouth A et al (2004) Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Amnesty 51:417–425CrossRefGoogle Scholar
  28. 28.
    Savakis EC (2003) WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. Transfusion 43:963–973CrossRefGoogle Scholar
  29. 29.
    Savakis EC (2002) Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting. Transfusion Med Rev 16:304–314CrossRefGoogle Scholar
  30. 30.
    Fisher M, Chapman JR, Ting A et al (1985) Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions. Vox Sang 49:331–335PubMedCrossRefGoogle Scholar
  31. 31.
    Marshall JC (1997) The multiple organ dysfunction (MOD) score. Sepsis 1:49–52CrossRefGoogle Scholar
  32. 32.
    Graziano C (2000) FDA “not backing away” from universal leukoreduction. CAP Today 14:5–6Google Scholar
  33. 33.
    Paxton A (2000) Universal leukoreduction—fix or folly? CAP Today 14:1Google Scholar
  34. 34.
    Houbiers JG, Brant A, van de Watering LM et al (1994) Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat depleted blood in surgery for colorectal cancer. Lancet 344:573–578PubMedCrossRefGoogle Scholar
  35. 35.
    Offner PJ, Moore EE, Biffl WL et al (2002) Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg 137:711–717PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2009

Authors and Affiliations

  • Michael S. Englehart
    • 1
  • S. David Cho
    • 1
  • Melanie S. Morris
    • 1
  • Arvin C. Gee
    • 1
  • Gordon Riha
    • 1
  • Samantha J. Underwood
    • 1
  • Jerome A. Differding
    • 1
  • Nick D. Luem
    • 1
  • Tracy T. Wiesberg
    • 1
  • Lynn K. Boshkov
    • 2
  • Martin A. Schreiber
    • 1
  1. 1.Department of SurgeryOregon Health & Science UniversityPortlandUSA
  2. 2.Department of PathologyOregon Health & Science UniversityPortlandUSA

Personalised recommendations